miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

miRagen Therapeutics (NASDAQ: MGEN) announced that its CEO, William S. Marshall, Ph.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 1:10 p.m. ET. A live webcast will be available on the company's investors page, with a replay also accessible post-event.

miRagen focuses on RNA-targeted therapies, with candidates in clinical stages including cobomarsen, remlarsen, and MRG-110, aimed at treating various cancers and fibrotic conditions.

BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 1:10 p.m. ET.

A live webcast of the event will be available on the investors page of the miRagen’s web site at  http://investors.miragen.com/events/.  Following the live webcast, a replay will also be available on miRagen’s website.

About miRagen Therapeutics

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen’s clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of miR-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of miR-92, is miRagen’s product candidate for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety, and manufacturability of the product candidate in preclinical studies. For more information, please visit www.miragen.com. For information on clinical trials please visit www.clinicaltrials.gov.

Investor Relations Contact:                                                 
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

When will miRagen present at the 2020 Wedbush PacGrow Healthcare Virtual Conference?

miRagen Therapeutics will present on August 12, 2020, at 1:10 p.m. ET.

What is the focus of miRagen Therapeutics?

miRagen Therapeutics focuses on discovering and developing RNA-targeted therapies for diseases with high unmet medical needs.

What are the clinical-stage product candidates of miRagen?

miRagen has three clinical-stage candidates: cobomarsen for certain cancers, remlarsen for pathological fibrosis, and MRG-110 for heart failure.

Where can I watch the miRagen presentation webcast?

The live webcast of the presentation can be found on miRagen's investors page at their official website.

What is cobomarsen used to treat?

Cobomarsen is used for the treatment of certain cancers by inhibiting miR-155.